For instance, the PROSPER (Prospective Study of Pravastatin in Elderly at Risk) trial with pravastatin showed a trend toward a lower number of new infarcts in the treatment arm but failed to demonstrate an effect on the progression of WMH volumes ( 42 ).
1
—
—